title: A Cost Effectiveness Analysis of Everolimus Plus Exemestane Compared to Chemotherapy Agents for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom.
authors.affiliation: Novartis Pharmaceuticals UK Limited, Camberley, UK.
authors.forename: Z
authors.initials: Z
authors.lastname: Polanyi
authors.affiliation: HEOR Solutions, London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Dale
authors.affiliation: York Health Economics Consortium, York, UK.
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.affiliation: York Health Economics Consortium, York, UK.
authors.forename: L
authors.initials: L
authors.lastname: Lewis
authors.affiliation: York Health Economics Consortium, York, UK.
authors.forename: J
authors.initials: J
authors.lastname: Glanville
authors.affiliation: Novartis Pharmaceuticals UK Limited, Camberley, UK.
authors.forename: J
authors.initials: J
authors.lastname: Vieira
authors.affiliation: Novartis Pharmaceuticals UK Limited, Camberley, UK.
authors.forename: D
authors.initials: D
authors.lastname: Chandiwana